We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Detection Method Diagnoses Ovarian Cancer from Blood, Urine and Saliva Samples

By LabMedica International staff writers
Posted on 10 Jul 2023

Detecting ovarian cancer in its preliminary stages, when it's most effectively treatable, poses a significant challenge. More...

One potential method for identifying this cancer is through the analysis of extracellular vesicles (EVs), with a specific focus on small proteins known as exosomes that are discharged from the tumor. These proteins, being extracellular, can be gathered from body fluids such as blood, urine, and saliva. However, the practical application of these biomarkers has been hampered by a scarcity of reliable markers for ovarian cancer detection. Now, researchers have uncovered three previously undiscovered membrane proteins associated with ovarian cancer. Utilizing a novel technology of polyketone-coated nanowires, the research team successfully isolated these proteins, leading to a new detection approach for ovarian cancer detection.

The research, conducted at Nagoya University (Nagoya, Japan) involved extracting both small and medium/large EVs from high-grade serous carcinoma (HGSC), the most prevalent form of ovarian cancer. The researchers then analyzed them using liquid chromatography-mass spectrometry. Although the initial phase of the research was demanding and the validation of the identified proteins was particularly challenging, the researchers' persistent efforts paid off. After examining various antibodies, they finally identified suitable targets. The findings showed that small and medium/large EVs carry distinctly different molecules, and further study found that the small EVs make better biomarkers than their larger counterparts. The researchers identified FRα, Claudin-3, and TACSTD2 as the membrane proteins present in the small EVs connected to HGSC.

Following the successful identification of these proteins, the research team turned their attention to capturing EVs in a manner that would enable cancer detection. To achieve this, they developed polyketone chain-coated nanowires (pNWs), a technology particularly effective for extracting exosomes from blood samples. However, crafting the pNWs was not a straightforward process. The team had to experiment with multiple coatings before settling on polyketones, a completely new material for this application. Eventually, their hard work paid off as the polyketones proved to be a perfect match.

“Our findings showed that each of the three identified proteins is useful as a biomarker for HGSCs,” said Akira Yokoi of the Nagoya University Graduate School of Medicine who led the research group. “The results of this research suggest that these diagnostic biomarkers can be used as predictive markers for specific therapies. Our results allow doctors to optimize their therapeutic strategy for ovarian cancer, therefore, they may be useful for realizing personalized medicine.”

Related Links:
Nagoya University


Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Epstein-Barr Virus Test
Mononucleosis Rapid Test
New
Unstirred Waterbath
HumAqua 5
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: Schematic diagram of multimodal single-cell MSI using tapping-mode scanning probe electrospray ionization (Photo courtesy of Yoichi Otsuka)

New Technology Improves Understanding of Complex Biological Samples

Tissues are composed of a complex mixture of various cell types, which complicates our understanding of their biological roles and the study of diseases. Now, a multi-institutional team of researchers... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.